Nuvalent (NASDAQ:NUVL) Shares Down 10.2%
Nuvalent (NASDAQ:NUVL) Shares Down 10.2%
Nuvalent, Inc. (NASDAQ:NUVL – Get Rating) shares fell 10.2% during mid-day trading on Thursday . The stock traded as low as $28.89 and last traded at $29.06. 3,382 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 217,664 shares. The stock had previously closed at $32.35.
納斯達克：NUVL-GET評級公司股價週四午盤下跌10.2%。該股一度跌至28.89美元，最後報29.06美元。午盤成交量為3,382股，較217,664股的平均成交量下降98%。該股此前收盤價為32.35美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Separately, BMO Capital Markets lifted their price objective on shares of Nuvalent from $28.00 to $50.00 and gave the stock a "buy" rating in a research note on Friday, October 28th.
另外，蒙特利爾銀行資本市場在10月28日(星期五)的一份研究報告中將Nuvalal的股票目標價從28.00美元上調至50.00美元，並給予該股“買入”評級。
Nuvalent Stock Down 7.9 %
新價股票下跌7.9%
The firm's 50-day moving average price is $28.22 and its two-hundred day moving average price is $19.75. The firm has a market capitalization of $1.68 billion, a PE ratio of -21.42 and a beta of 1.60.
該公司的50日移動均線價格為28.22美元，200日移動均線價格為19.75美元。該公司的市值為16.8億美元，市盈率為-21.42，貝塔係數為1.60。
Insider Transactions at Nuvalent
Nuvalal的內幕交易
Institutional Trading of Nuvalent
新價的機構性交易
Several institutional investors have recently made changes to their positions in NUVL. California State Teachers Retirement System boosted its holdings in shares of Nuvalent by 35.0% during the first quarter. California State Teachers Retirement System now owns 7,811 shares of the company's stock worth $108,000 after purchasing an additional 2,024 shares during the period. SG Americas Securities LLC acquired a new stake in Nuvalent in the third quarter valued at approximately $114,000. American International Group Inc. lifted its stake in Nuvalent by 59.8% in the first quarter. American International Group Inc. now owns 9,098 shares of the company's stock valued at $126,000 after acquiring an additional 3,406 shares during the last quarter. Credit Suisse AG lifted its stake in Nuvalent by 42,088.9% in the third quarter. Credit Suisse AG now owns 7,594 shares of the company's stock valued at $148,000 after acquiring an additional 7,576 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its stake in Nuvalent by 65.6% in the first quarter. New York State Common Retirement Fund now owns 12,922 shares of the company's stock valued at $179,000 after acquiring an additional 5,120 shares during the last quarter. 95.07% of the stock is currently owned by institutional investors and hedge funds.
幾家機構投資者最近改變了他們在NUVL的頭寸。加利福尼亞州教師退休制度在第一季度將其持有的Nuvalal股票增加了35.0%。加利福尼亞州教師退休系統現在擁有該公司7811股股票，價值10.8萬美元，在此期間又購買了2024股。SG America Securities LLC在第三季度收購了Nuvalal的新股份，價值約為11.4萬美元。今年第一季度，美國國際集團(American International Group Inc.)增持了Nuvality 59.8%的股份。美國國際集團(American International Group Inc.)在上個季度增持了3,406股後，現在持有9,098股該公司股票，價值12.6萬美元。瑞士信貸(Credit Suisse AG)在第三季度將其在Nuvalal的持股比例提高了42088.9%。瑞士信貸(Credit Suisse AG)在上個季度增持了7,576股後，目前持有該公司7,594股股票，價值14.8萬美元。最後，紐約州共同退休基金在第一季度將其在Nuvalal的持股增加了65.6%。紐約州共同退休基金現在擁有12,922股該公司的股票，價值179,000美元，在上個季度額外購買了5,120股。95.07%的股票目前由機構投資者和對衝基金持有。
Nuvalent Company Profile
新價公司簡介
(Get Rating)
(獲取評級)
Nuvalent, Inc, a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial.
新價公司是一家臨牀階段的生物製藥公司，為癌症患者開發療法。其主要候選產品有NVL-520，這是一種腦穿透性ROS1選擇性抑制劑，用於抑制ROS1融合，這種融合表達正常的ROS1激活域，沒有任何耐藥突變，並且在存在對已批准和正在研究的ROS1抑制劑產生耐藥性的突變時仍保持活性，該藥處於I期開發中；以及NVL-655，一種腦滲透性ALK選擇性抑制劑，用於解決緊急治療耐藥性、中樞神經系統相關不良事件和腦轉移等臨牀挑戰，這些挑戰可能限制正在進行I/II期臨牀試驗的第一、第二和第三代ALK抑制劑的使用。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Nuvalent (NUVL)
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
- 免費獲取StockNews.com關於Nuvalal的研究報告(NUVL)
- 現在不是購買Lennar的時候，但時機即將到來
- 馬倫汽車公司改變遊戲規則的消息
- 通貨膨脹和能源危機是兩列相撞的貨運列車--以下是如何做好準備的
- 企業產品合作伙伴是否得到公平評價？
- WhatsApp合作伙伴關係是否會提振MercadoLibre的收益？
Receive News & Ratings for Nuvalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvalent and related companies with MarketBeat.com's FREE daily email newsletter.
接受《新價日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對Nuvalal及相關公司評級的每日簡要摘要。